KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CRISPR Therapeutics AG (CRSP) Net Margin: 2015-2025

Historic Net Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to -11,973.12%.

  • CRISPR Therapeutics AG's Net Margin rose 230695.00% to -11,973.12% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,382.50%, marking a year-over-year decrease of 124920.00%. This contributed to the annual value of -1,093.34% for FY2024, which is 104366.00% down from last year.
  • CRISPR Therapeutics AG's Net Margin amounted to -11,973.12% in Q3 2025, which was up 48.79% from -23,380.83% recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Net Margin high stood at 84.29% for Q2 2021, and its period low was -1,880,950.00% during Q4 2022.
  • Moreover, its 3-year median value for Net Margin was -13,126.59% (2024), whereas its average is -11,329.84%.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Net Margin crashed by 187,985,497bps in 2022, and later spiked by 188,097,913bps in 2023.
  • Quarterly analysis of 5 years shows CRISPR Therapeutics AG's Net Margin stood at -1,095.03% in 2021, then slumped by 187,985,497bps to -1,880,950.00% in 2022, then spiked by 188,097,913bps to 29.13% in 2023, then slumped by 25,051bps to -221.38% in 2024, then surged by 230,695bps to -11,973.12% in 2025.
  • Its last three reported values are -11,973.12% in Q3 2025, -23,380.83% for Q2 2025, and -15,722.08% during Q1 2025.